Pentapeptide-18
A synthetic enkephalin-mimicking pentapeptide that reduces acetylcholine release at the neuromuscular junction, relaxing facial muscles and smoothing expression wrinkles. Reduces wrinkle depth by ~11% alone and up to 25% when combined with Argireline.
What is Pentapeptide-18?
Pentapeptide-18 (Leuphasyl) is a synthetic pentapeptide with the sequence Tyr-D-Ala-Gly-Phe-Leu, developed by Lipotec (now Lubrizol) as a cosmeceutical anti-wrinkle ingredient. Its design is based on the natural enkephalin opioid pentapeptides — leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) and methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) — with a D-alanine substitution at position 2 that improves enzymatic stability. Like natural enkephalins, it binds to opioid receptors on presynaptic nerve terminals, triggering a G-protein cascade that closes calcium channels and opens potassium channels. This reduces calcium influx, preventing synaptic vesicle fusion and decreasing acetylcholine release across the neuromuscular junction. The result is reduced muscle contraction intensity and softer expression wrinkles — particularly forehead lines and crow's feet. Unlike Argireline (which blocks SNARE complex assembly) or Syn-Ake (which blocks the postsynaptic receptor), Pentapeptide-18 works upstream by mimicking the body's own inhibitory signaling.
What Pentapeptide-18 Is Investigated For
Pentapeptide-18 (Leuphasyl) is a topical cosmeceutical enkephalin mimetic used to reduce expression wrinkles — forehead lines, crow's feet, glabellar creases — by modulating presynaptic acetylcholine release at the neuromuscular junction, and is commonly stacked with Argireline for a synergistic anti-wrinkle effect. The strongest evidence is in small clinical studies of the peptide at 2–5% concentrations: Dragomirescu et al. (2014) reported ~34.7% forehead wrinkle-depth reduction at 2% over 60 days, and manufacturer data shows ~11% reduction with 5% Leuphasyl alone and up to ~25% when combined with Argireline over 28 days. The enkephalin/δ-opioid-receptor presynaptic inhibition mechanism is pharmacologically sound, though whether meaningful receptor engagement occurs through intact skin at cosmeceutical concentrations is the central unresolved question. Most published efficacy data comes from manufacturer-sponsored work with thin independent replication, and effect sizes are substantially smaller than botulinum toxin (50–80% reduction within days). Genuine cosmetic active with documented signal, not 'topical Botox.'
History & Discovery
Pentapeptide-18 (Leuphasyl) was developed by Lipotec S.A. in Barcelona — the same Spanish peptide company behind Argireline (acetyl hexapeptide-8) and SNAP-8 (acetyl octapeptide-3) — and trademarked in the mid-2000s as a cosmeceutical anti-wrinkle ingredient. The design rationale stepped sideways from the SNARE-targeting approach Lipotec had used for Argireline: instead of competing with SNAP-25 to inhibit vesicle fusion, Leuphasyl was designed to mimic the body's own enkephalin opioid pentapeptides — leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu) and methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) — which engage opioid receptors on presynaptic motor nerve terminals to dampen neurotransmitter release. Lipotec's design substituted D-alanine for glycine at position 2 (Tyr-D-Ala-Gly-Phe-Leu) to confer resistance to enzymatic degradation by aminopeptidases — a stability strategy borrowed from the broader opioid peptide pharmacology literature. The marketing positioning was distinct from Argireline: while Argireline blocked the SNARE complex downstream, Leuphasyl was pitched as an upstream modulator that worked via the same inhibitory pathway the body itself uses to dial down nerve signaling. The two peptides were positioned as synergistic — manufacturer data claimed combination use produced larger wrinkle reduction than either alone. Lipotec was acquired by Lubrizol in 2012, and Leuphasyl continues to be marketed under that umbrella as Pentapeptide-18. Independent peer-reviewed efficacy data on the peptide remains thin.
How It Works
Before your facial muscles contract, a nerve signal triggers the release of acetylcholine — the chemical messenger that tells the muscle to move. Your body naturally has enkephalins, small peptides that can dial down this nerve signaling. Pentapeptide-18 mimics these enkephalins: it binds to receptors on the nerve ending and tells the cell to reduce its activity. With less acetylcholine released, your facial muscles contract less intensely, and the expression wrinkles they create (like forehead lines and crow's feet) gradually soften.
Pentapeptide-18 (H-Tyr-D-Ala-Gly-Phe-Leu-OH, MW 569.6 g/mol) is a synthetic analog of leucine-enkephalin with a D-alanine substitution at position 2 that confers resistance to aminopeptidase degradation. It functions as an agonist at delta-opioid receptors (DOR) on presynaptic motor nerve terminals. Upon binding, the receptor couples to inhibitory Gi/Go proteins, activating a signaling cascade that closes voltage-gated calcium channels (VGCCs) and opens inwardly rectifying potassium channels (GIRKs). Reduced Ca2+ influx prevents synaptic vesicle docking and fusion with the presynaptic membrane, thereby inhibiting acetylcholine exocytosis across the neuromuscular junction. This presynaptic mechanism is complementary to Argireline's SNARE complex inhibition (also presynaptic but downstream) and Syn-Ake's postsynaptic nicotinic receptor antagonism, enabling multi-target combination strategies. A 2026 computational study (PMID: 41722287) analyzed Pentapeptide-18's interactions with five aging-related signaling pathways — TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB — using FTIR/Raman spectroscopy, DFT calculations, and molecular dynamics simulations, supporting broader anti-aging activity beyond neuromuscular modulation. Additionally, Park et al. (2020) demonstrated that D-tyrosine-containing derivatives of Pentapeptide-18 reduce melanin content and tyrosinase activity in melanocytes by 18-25%, suggesting dual anti-wrinkle and skin-brightening potential (PMID: 31937863).
Evidence Snapshot
Human Clinical Evidence
Limited. Manufacturer data (Lipotec) from an in vivo study showed 5% Leuphasyl applied twice daily for 28 days reduced wrinkle depth by ~11%, and combination with 5% Argireline achieved ~25% average reduction (up to 47%). Dragomirescu et al. (2014) evaluated 2% Leuphasyl cream applied twice daily for 60 days using digital imaging and silicone replicas, reporting 34.7% wrinkle depth reduction on the forehead and 28.4% around the eyes, with an overall average reduction of 11.31% at lower concentrations over 28 days. A 2024 study incorporated Pentapeptide-18 into solid lipid nanoparticles with retinol, demonstrating stable delivery and anti-aging effects in an 8-week trial (PMID: 39337562). All studies are manufacturer-sponsored or small-scale.
Animal / Preclinical
Limited. Primarily in vitro: enkephalin receptor binding demonstrated in cell-based assays with downstream calcium channel modulation confirmed. Park et al. (2020) showed D-tyrosine-modified Pentapeptide-18 reduced melanin content by 18-25% and tyrosinase activity in MNT-1 melanoma cells and primary melanocytes (PMID: 31937863). A 2026 computational study used molecular docking, dynamics simulations, and ADMET analysis to characterize Pentapeptide-18 interactions with TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB pathway targets (PMID: 41722287).
Mechanistic Rationale
Moderate. The enkephalin-mediated presynaptic inhibition mechanism is pharmacologically well-established for endogenous opioid peptides. The D-Ala2 substitution improving enzymatic stability is a proven strategy from opioid peptide pharmacology. Whether sufficient receptor engagement occurs through topical application at cosmeceutical concentrations to produce clinically meaningful neuromuscular modulation is the central question — the mechanism is sound, but transdermal bioavailability at the target site is uncertain.
Research Gaps & Open Questions
What the current literature has not yet settled about Pentapeptide-18:
- 01Independent, non-industry-funded human trials on Pentapeptide-18 specifically — most efficacy claims trace back to Lipotec/Lubrizol-associated studies, with the Dragomirescu et al. (2014) study being one of the few published independent evaluations.
- 02Direct head-to-head comparisons with botulinum toxin (the implicit comparator), Argireline, Syn-Ake, and Vialox at matched concentrations and durations.
- 03Real-world skin-penetration and target-site quantification — whether the pentapeptide actually reaches presynaptic δ-opioid receptors at facial neuromuscular junctions in clinically meaningful concentrations from topical application is the central unresolved question.
- 04Long-term human data — most published work spans 28- to 60-day windows; multi-month and multi-year continuous use has not been studied as a distinct safety or efficacy question.
- 05Whether the manufacturer's claimed Argireline + Leuphasyl synergy (~25% combined vs. ~11% alone) holds up in independent trials at multiple concentrations and durations.
- 06Translation of the in vitro D-tyrosine-modified Pentapeptide-18 anti-melanogenic findings (Park et al. 2020) into clinical pigmentation endpoints — the dual anti-wrinkle/skin-brightening positioning is intriguing but unproven in humans.
- 07Whether the 2026 computational pathway analyses (TGF-β, TNF-α, MAPK, PI3K/AKT, NF-κB) translate into measurable in vivo anti-aging effects beyond neuromuscular modulation.
Forms & Administration
Pentapeptide-18 is used topically in cosmeceutical formulations — serums, creams, and eye treatments. Standard concentrations range from 2-5% in finished products. Most effective when combined with Argireline (acetyl hexapeptide-8) for synergistic expression line reduction, and sometimes paired with Matrixyl (collagen stimulation) or Syn-Ake (postsynaptic receptor blocking) for multi-target anti-aging. Applied to clean skin, typically twice daily. No prescription required for cosmeceutical products. Advanced delivery systems such as solid lipid nanoparticles have been explored to improve skin penetration and stability.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Cosmetic formulations typically include Pentapeptide-18 at 2–5% of the finished product. Dragomirescu et al. (2014) determined the minimum effective concentration for visible wrinkle reduction to be 2% applied twice daily; manufacturer (Lipotec) efficacy data has used 5% concentration. Most over-the-counter Leuphasyl-containing serums fall in the 2–5% range, often combined with other peptides at lower individual concentrations within multi-peptide formulations.
Frequency
Applied topically once or twice daily to clean skin, typically targeting expression-line areas (forehead, glabella, crow's feet). Trial protocols have used twice-daily application for 28 days (manufacturer 5% study) to 60 days (Dragomirescu 2% study) before measuring wrinkle-depth and skin-roughness endpoints.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Continuous indefinite use. Pentapeptide-18 is a maintenance cosmetic active — the enkephalin receptor agonism only modulates neurotransmitter release while the peptide is present at the receptor, so measurable benefit requires continued application. No cycling strategy is described in the cosmetic literature.
Protocol Notes
Skin penetration is the central practical caveat. The peptide has a molecular weight around 570 Da — close to the conventional ~500 Da rule-of-thumb threshold for passive transdermal penetration — and is hydrophilic. The pharmacological target — δ-opioid receptors on presynaptic motor nerve terminals at neuromuscular junctions in facial musculature — sits well below the epidermal layers that topical peptides typically reach, which is the fundamental gap between in vitro receptor binding and modest in vivo wrinkle-depth effects. Formulation matters meaningfully. Solid lipid nanoparticle delivery (combined with retinol in a 2024 study) has been explored to improve transdermal stability and delivery. Pentapeptide-18 is most commonly stacked with Argireline, where the rationale is mechanistically clean: Argireline blocks SNARE complex assembly downstream, while Pentapeptide-18 reduces calcium influx upstream by mimicking enkephalins — different points in the same neuromuscular cascade. Manufacturer data shows the combination produces larger reductions (~25% vs. ~11% for Leuphasyl alone) than either peptide individually. Pentapeptide-18 is also commonly co-formulated with matrikine peptides (Matrixyl, Syn-Coll) and with postsynaptic blockers (Syn-Ake, Vialox).
Pentapeptide-18 is a cosmetic ingredient, not a drug. It is not FDA-approved to treat or prevent any medical condition, and cosmetic claims permitted on labels are limited to appearance-related language. Despite mimicking enkephalin structure, topical use at cosmetic concentrations does not produce systemic opioid effects — this is not an opioid analgesic and has no abuse potential at topical cosmetic exposure. Do not inject cosmetic peptide products.
Timeline of Effects
Onset
Published trials begin to report measurable wrinkle-depth reduction at 28 days of twice-daily application. Dragomirescu et al. (2014) measured significant reductions at 60 days using digital imaging and silicone replicas of facial topography. Immediate 'tightening' or smoothing sensations within minutes of application come from film-forming polymers and humectants in the vehicle, not from real-time receptor engagement.
Peak Effect
Maximum measured effect in published studies is reported at 28–60 days. Manufacturer 5% Leuphasyl alone produced ~11% wrinkle-depth reduction at 28 days; combined with 5% Argireline, reductions reached ~25% on average (up to 47% in some subjects). Dragomirescu et al. (2014) reported 34.7% wrinkle-depth reduction on the forehead and 28.4% around the eyes at 60 days using 2% concentration. Larger figures than Argireline alone, but still well below botulinum toxin's 50–80% reductions within days from injection.
After Discontinuation
Effects recede over weeks as the peptide is cleared and δ-opioid receptor signaling returns to baseline. Most users describe a gradual return toward baseline expression-line depth within 4–8 weeks of stopping use. There is no described withdrawal or rebound pattern — and no opioid-style discontinuation syndrome, because systemic exposure from topical cosmetic use is negligible and the receptor engagement is localized to the application area.
Common Questions
Who Pentapeptide-18 Is NOT For
- •Broken, irritated, or actively inflamed skin — wait until the skin barrier is intact before applying cosmetic peptide serums; application to compromised skin increases irritation potential and any systemic absorption (which remains negligible even so).
- •Known hypersensitivity to Pentapeptide-18 or to other components of the cosmetic vehicle (preservatives, fragrances, emulsifiers); contact dermatitis is uncommon but reported.
- •Pregnancy and breastfeeding — topical cosmetic use on intact skin is generally considered low-risk, but there is no dedicated safety data in pregnancy. The opioid-mimetic structure makes a conservative default to minimize use during this window reasonable, even though systemic absorption is negligible.
- •Pediatric use — no data and no clinical reason for children or adolescents to use anti-wrinkle peptides.
- •Do not inject cosmetic Pentapeptide-18 preparations — these are not sterile injectable products, not manufactured under injectable standards, and there is no clinical basis for injection.
- •Patients with pre-existing neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) should consult a clinician before using neuromuscular-targeting cosmetic peptides, even though systemic exposure from topical use is expected to be negligible.
Drug & Supplement Interactions
Documented pharmacological drug interactions for topical Pentapeptide-18 are minimal. Systemic absorption from typical topical use is low enough that meaningful interaction with oral or injected medications is not expected. The opioid-mimetic structure does not translate into systemic opioid effects at topical cosmetic exposure, and there is no documented interaction with prescription opioid analgesics, opioid antagonists (naloxone, naltrexone), or buprenorphine at the level of topical use. The practical interaction space is topical layering with other actives. Pentapeptide-18 is compatible with most cosmetic ingredients — niacinamide, hyaluronic acid, ceramides, and other peptides layer readily. Co-formulation with Argireline is the most common stacking pattern and is mechanistically complementary (presynaptic upstream modulation + presynaptic downstream SNARE inhibition). Pairing with postsynaptic blockers (Syn-Ake, Vialox) hits a third point in the neuromuscular cascade and is also mechanistically distinct. Layering with matrikine peptides (Matrixyl, Syn-Coll) combines independent mechanisms. High-concentration L-ascorbic acid (vitamin C) is acidic enough that concurrent same-layer application can destabilize peptide actives and is typically used at a different time of day. Strong AHA/BHA exfoliation on the same evening as Pentapeptide-18 can reduce peptide activity at the surface and increase irritation. Patients receiving botulinum toxin injection generally do not need to stop Pentapeptide-18 beforehand.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
- • Topical efficacy depends on skin penetration, which varies by formulation and delivery system
- • Most clinical data comes from manufacturer-sponsored studies (Lipotec/Lubrizol)
- • Over-the-counter products vary widely in concentration and formulation quality
What We Don't Know
Long-term effects of chronic topical enkephalin receptor modulation on facial nerve signaling are not studied. Whether clinically meaningful presynaptic inhibition occurs through intact skin at cosmeceutical concentrations remains debated — in vitro receptor binding is demonstrated, but in vivo transdermal delivery efficiency is uncertain. Independent clinical replication beyond manufacturer data is limited.
Legal Status
United States
Regulated as a cosmetic ingredient under FDA cosmetic law, not as a drug. Over-the-counter sale in finished cosmetic formulations is permitted without prescription. Pentapeptide-18 is INCI-listed and appears in many over-the-counter anti-wrinkle products, often within multi-peptide formulations. Not approved as a drug for wrinkles or any other medical indication — labels are limited to cosmetic appearance claims. Despite mimicking enkephalin structure, the peptide is not scheduled or restricted in any way at the topical cosmetic level — there is no abuse potential from topical exposure and no DEA classification.
International
Permitted as a cosmetic ingredient across the EU (CosIng database), UK, Canada, Australia, Japan, and most major markets. Cosmetic ingredient safety reviews have not raised concerns at typical formulation levels. The enkephalin-mimetic structure has not triggered controlled-substance regulatory treatment in any jurisdiction.
Sports & Competition
Not listed on the WADA Prohibited List and not a realistic doping concern. Topical cosmetic peptides have negligible systemic exposure relevant to performance, and the localized δ-opioid receptor engagement at facial neuromuscular junctions does not produce systemic opioid effects.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Pentapeptide-18 is 'topical Botox' and produces comparable results.
Reality
The marketing framing is misleading. Pentapeptide-18 mimics enkephalins to modulate (not block) acetylcholine release at presynaptic terminals; botulinum toxin enzymatically cleaves SNAP-25 to abolish acetylcholine release entirely. Botulinum toxin produces 50–80% wrinkle reduction within days; topical Pentapeptide-18 produces ~11–35% reductions over weeks depending on concentration and combination. It is not a substitute for injection.
Myth
Pentapeptide-18 is an opioid and could cause systemic opioid effects, dependence, or be detected on a drug screen.
Reality
Pentapeptide-18 mimics enkephalin structure and engages δ-opioid receptors at the local neuromuscular junction in facial skin, but topical cosmetic application produces negligible systemic absorption. It does not cross the blood-brain barrier in any clinically relevant amount, does not produce analgesic, euphoric, or addictive effects, and is not detected on standard opioid drug screens. There is no controlled-substance regulation of the peptide in any jurisdiction.
Myth
Stacking Pentapeptide-18 with Argireline doubles or triples the wrinkle effect.
Reality
Manufacturer data does support meaningful additivity for the Argireline + Pentapeptide-18 combination — roughly ~25% combined vs. ~11% for Leuphasyl alone in their 28-day study, which is mechanistically plausible because the peptides target different points in the same neuromuscular cascade. But the additivity is modest, comes from manufacturer-sponsored work, and 'doubling' or 'tripling' overstates what the data shows.
Myth
Higher-concentration Pentapeptide-18 products give proportionally better results.
Reality
Stratum corneum permeation is the rate-limiting step, not vehicle concentration. Above the manufacturer's 5% range, additional peptide in the serum mainly increases label appeal. Vehicle and formulation choices (encapsulation, penetration enhancers, occlusion, solid lipid nanoparticle delivery) drive delivered dose more than nominal label percentage.
Myth
Pentapeptide-18 can be safely injected for stronger effect.
Reality
Cosmetic Pentapeptide-18 preparations are not sterile injectable products, not manufactured under injectable standards, and there is no authorized injectable category. Injecting cosmetic peptide products carries documented infection risk — published case reports exist for related cosmetic peptides causing serious facial mycobacterial infection after unlicensed injection.
Published Research
6 studiesPentapeptide-18 as an anti-aging candidate: Spectroscopic characterization and molecular interaction analysis.
2026 computational study analyzing Pentapeptide-18 interactions with TGF-β, TNF-α, MAPK, PI3K/AKT, and NF-κB pathways via molecular docking and dynamics simulations.
Solid Lipid Nanoparticles Incorporated with Retinol and Pentapeptide-18 — Optimization, Characterization, and Cosmetic Application.
2024 study optimizing Pentapeptide-18 delivery in solid lipid nanoparticles with retinol for enhanced anti-aging cosmetic application.
D-tyrosine adds an anti-melanogenic effect to cosmetic peptides.
Park et al. (2020) demonstrated that D-tyrosine-modified Pentapeptide-18 reduces melanin content and tyrosinase activity in melanocytes.
The Efficiency and Safety of Leuphasyl — A Botox-Like Peptide.
Dragomirescu et al. (2014) evaluated optimal concentration, safety, and efficacy of Leuphasyl for wrinkle reduction using digital imaging and silicone replicas.
Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy.
Comprehensive review covering Leuphasyl mechanism, synergy with Argireline, and classification among neurotransmitter inhibitor peptides.
Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review.
2025 review summarizing Pentapeptide-18 clinical evidence, optimal concentration data, and combination strategies with Argireline.
Quick Facts
- Class
- Cosmeceutical Peptide
- Tier
- D
- Evidence
- Preliminary
- Safety
- Moderate Data
- Updated
- Apr 2026
- Citations
- 6PubMed
Also known as
Tags
Peptide Families
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.